KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aquestive Therapeutics (AQST) Revenue (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Revenue data on record, last reported at $13.0 million in Q4 2025.

  • For Q4 2025, Revenue rose 9.67% year-over-year to $13.0 million; the TTM value through Dec 2025 reached $44.5 million, down 22.61%, while the annual FY2025 figure was $44.5 million, 22.61% down from the prior year.
  • Revenue reached $13.0 million in Q4 2025 per AQST's latest filing, up from $12.8 million in the prior quarter.
  • Across five years, Revenue topped out at $20.1 million in Q2 2024 and bottomed at $2.0 million in Q2 2021.
  • Average Revenue over 5 years is $11.5 million, with a median of $12.0 million recorded in 2024.
  • Peak YoY movement for Revenue: skyrocketed 300.0% in 2021, then crashed 50.23% in 2025.
  • A 5-year view of Revenue shows it stood at $11.1 million in 2021, then fell by 3.57% to $10.7 million in 2022, then increased by 23.63% to $13.2 million in 2023, then fell by 10.14% to $11.9 million in 2024, then increased by 9.67% to $13.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $13.0 million in Q4 2025, $12.8 million in Q3 2025, and $10.0 million in Q2 2025.